Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Heart Journal

• Publication date

  2013-09-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurheartj/eht256PMID 23864135
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alterations in cardiac DNA methylation in human dilated cardiomyopathy

  2013cited by this paper
• Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients

  2013cited by this paper
• Refining diagnostic microRNA signatures by whole-miRNome kinetic analysis in acute myocardial infarction.

  2013cited by this paper
• Heparin selectively affects the quantification of microRNAs in human blood samples.

  2013cited by this paper
• NON-CARDIOMYOCYTE MIRNAS IN HEART FAILURE

  2013cited by this paper
• Serum levels of microRNAs in patients with heart failure

  2012cited by this paper
• MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Leukocyte labile iron pool in patients with systolic heart failure.

  2012cited by this paper
• Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study.

  2012cited by this paper
• Non-cardiomyocyte microRNAs in heart failure.

  2012cited by this paper
• Inflammation in Myocardial Diseases

  2012cited by this paper
• Identification of Suitable Reference Genes for qPCR Analysis of Serum microRNA in Gastric Cancer Patients

  2012cited by this paper
• The Expression of microRNA and microRNA Clusters in the Aging Heart

  2012cited by this paper
• Plasma Levels of Liver-Specific miR-122 Is Massively Increased in a Porcine Cardiogenic Shock Model and Attenuated by Hypothermia

  2012cited by this paper
• A cellular microRNA, let-7i, is a novel biomarker for clinical outcome in patients with dilated cardiomyopathy.

  2011cited by this paper
• Population differences in microRNA expression and biological implications

  2011cited by this paper
• Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure.

  2011cited by this paper
• HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).

  2011cited by this paper
• Toward the blood-borne miRNome of human diseases

  2011cited by this paper
• MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex

  2011cited by this paper
• HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).

  2011cited by this paper
• MiR423-5p As a Circulating Biomarker for Heart Failure

  2010cited by this paper
• MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction

  2010cited by this paper
• A dictionary on microRNAs and their putative target pathways

  2010cited by this paper
• Biomarkers for Chronic Heart Failure

  2009cited by this paper
• miRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments

  2009cited by this paper
• Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling Networks*

  2009cited by this paper
• Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support

  2009cited by this paper
• Multiple Sclerosis: MicroRNA Expression Profiles Accurately Differentiate Patients with Relapsing-Remitting Disease from Healthy Controls

  2009cited by this paper
• Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases

  2008cited by this paper
• Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care

  2008cited by this paper
• Microfluidic-based enzymatic on-chip labeling of miRNAs.

  2008cited by this paper
• Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure

  2008cited by this paper
• Utility of N terminal pro brain natriuretic peptide in elderly patients

  2006cited by this paper
• Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

  2005cited by this paper
• Intensified Cloning Efforts Have Revealed Numer

  2004cited by this paper
• Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction.

  1997cited by this paper
• Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.

  1997cited by this paper
• Support-Vector Networks

  1995cited by this paper

• Profiling of the microRNA transcriptome in feline whole blood

  2025cites this paper
• The emerging role of miRNAs in biological aging and age-related diseases

  2025cites this paper
• Decoding STAT3: a new frontier in understanding and treating hyperoxic lung injury

  2025cites this paper
• Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan–Meier-based individual patient data

  2025influential citation
• The European BestAgeing Study on microRNA candidates reveals distinct signatures with diagnostic and prognostic potential in cardiovascular disease

  2025cites this paper
• Early Myocardial Strain Reduction and miR-122-5p Elevation Associated with Interstitial Fibrosis in Anthracycline-Induced Cardiotoxicity

  2024cites this paper
• Exploring the role of pericardial miRNAs and exosomes in modulating cardiac fibrosis.

  2024cites this paper
• miRNAs orchestration of cardiovascular diseases - Particular emphasis on diagnosis, and progression.

  2023cites this paper
• miRNA-122 as a new player in cardiovascular disease

  2023cites this paper
• Advances in congestive heart failure biomarkers.

  2023cites this paper
• Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review.

  2022cites this paper
• Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine

  2022cites this paper
• The microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis

  2022cites this paper
• miR Profile of Chronic Right Ventricular Pacing: a Pilot Study in Children with Congenital Complete Atrioventricular Block

  2022cites this paper
• Epigenetic regulation of transcription factor binding motifs promotes Th1 response in Chagas disease cardiomyopathy

  2022cites this paper
• Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta‐analysis

  2022cites this paper
• Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy

  2022cites this paper
• Specific methylation marks in promoter regions are associated to the pathogenic process of Chronic Chagas disease Cardiomyopathy by modifying transcription factor binding patterns

  2021cites this paper
• Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression

  2021cites this paper
• Identification of novel circulating microRNAs in advanced heart failure by next‐generation sequencing

  2021cites this paper
• Cardiac‐specific overexpression of miR‐122 induces mitochondria‐dependent cardiomyocyte apoptosis and promotes heart failure by inhibiting Hand2

  2021cites this paper
• Circulating miR‐19b‐3p as a Novel Prognostic Biomarker for Acute Heart Failure

  2021cites this paper
• MicroRNA targets and biomarker validation for diabetes-associated cardiac fibrosis.

  2021cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2020cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2020cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2020cites this paper
• Epigenetic-sensitive liquid biomarkers and personalised therapy in advanced heart failure: a focus on cell-free DNA and microRNAs

  2020cites this paper
• A multivariable miRNA signature delineates the systemic hemodynamic impact of arteriovenous shunt placement in a pilot study

  2020cites this paper
• Biogenesis and mechanism of action of MicroRNAs as serum biomarkers in cardiovascular diseases

  2020cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2020cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2020cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2020cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2020cites this paper
• Anesthetic-induced myocardial conditioning: molecular fundamentals and scope.

  2020cites this paper
• Non-coding RNAs: The key detectors and regulators in cardiovascular disease.

  2020cites this paper
• Circulating whole genome miRNA expression corresponds to progressive right ventricle enlargement and systolic dysfunction in adults with tetralogy of Fallot

  2020cites this paper
• Role of MicroRNAs in Diagnosis, Prognosis, and Treatment of Acute Heart Failure: Ambassadors from Intracellular Zone

  2020cites this paper
• The Role of microRNAs in Heart Failure: A Systematic Review

  2020cites this paper
• Common diseases alter the physiological age-related blood microRNA profile

  2020cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure.

  2019cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Serum microRNA-1 and microRNA- 133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Lab Standards

  2019cites this paper
• Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Spring is in the air: seasonal profiles indicate vernal change of miRNA activity

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• The Effects of Regular Exercise on Circulating Cardiovascular-related MicroRNAs

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Country : Italy Final Report Summary-INHERITANCE ( INtegrated HEart Research In TrANslational genetics of dilated Cardiomyopathies in Europe )

  2019cites this paper
• Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Calcium as a Key Player in Arrhythmogenic Cardiomyopathy: Adhesion Disorder or Intracellular Alteration?

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2019cites this paper
• Epigenetic Biomarkers in Cardiovascular Diseases

  2019cites this paper
• Molecular and Cellular Biology of the Right Heart

  2018cites this paper
• MicroRNA in Chronic Kidney Disease and Heart Failure

  2018cites this paper
• The Effects of Exercise Training on Cardiovascular-related Circulating MicroRNAs

  2018cites this paper
• [MicroRNAs as Biomarkers of Cardiovascular Diseases].

  2018cites this paper
• Precision medicine for cardiovascular disease

  2018cites this paper
• Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics.

  2018cites this paper
• miRNA-based antiarrhythmics after myocardial ischaemic injury: Authors' reply.

  2018cites this paper
• At the heart of programming: the role of micro-RNAs

  2018cites this paper
• Significance of non-coding circular RNAs and micro RNAs in the pathogenesis of cardiovascular diseases

  2018cites this paper
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2018cites this paper
• Epigenetic biomarkers in cardiovascular disease

  2018cites this paper
• Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?

  2017cites this paper
• Cardiac Fibrosis and Arrhythmogenesis.

  2017cites this paper
• Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2017cites this paper
• The characterisation of circulating biomarkers and body composition before and after cardiac resynchronisation therapy in patients with chronic heart failure and their role in predicting response

  2017influential citation
• Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2017cites this paper
• miR-1231 exacerbates arrhythmia by targeting calciumchannel gene CACNA2D2 in myocardial infarction.

  2017cites this paper
• Novel Risk Markers and Risk Assessments for Cardiovascular Disease

  2017influential citation
• Serum microRNA-1 and microRNA-133 a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  2017cites this paper
• MicroRNAs as Clinical Biomarkers and Therapeutic Tools in Perioperative Medicine

  2017cites this paper
• miRNAs as biomarkers for diagnosis of heart failure

  2017cites this paper
• Uso de micro RNA en el manejo de la insuficiencia cardiaca

  2017cites this paper
• [Use of microRNAs in heart failure management].

  2017cites this paper
• MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential

  2017cites this paper
• Circulating microRNAs in heart failure

  2017cites this paper
• The Clinical Potential of Heart Failure–Related miRNAs

  2017cites this paper
• Community detection of non-ischemic stage B heart failure

  2017cites this paper
• microRNAs in cardiovascular disease – clinical application

  2017cites this paper
• MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation.

  2016cites this paper
• Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease.

  2016cites this paper
• Polyethyleneimine-coated quantum dots for miRNA delivery and its enhanced suppression in HepG2 cells

  2016cites this paper
• Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives.

  2016cites this paper
• microRNA assays for acute coronary syndromes

  2016cites this paper
• MicroRNA and Heart Failure

  2016influential citation
• Can circulating miRNAs live up to the promise of being minimal invasive biomarkers in clinical settings?

  2016cites this paper
• Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects

  2016cites this paper
• Signature of circulating microRNAs in patients with acute heart failure

  2016cites this paper
• Profiling of differentially expressed microRNAs in arrhythmogenic right ventricular cardiomyopathy

  2016cites this paper